Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — Maj 2024

Biotek-snakken — Maj 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
67 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • F Offline
    F Offline
    Fandel
    wrote on sidst redigeret af
    #20

    Godmorgen...

    1 Reply Last reply
    0
    • K Offline
      K Offline
      Kjølstad
      wrote on sidst redigeret af
      #21

      IRLAB: Offentliggjort i går: Samarbejdsaftale med McQuade Center for Strategic Research and Development, LCC (MSRD) om udvikling af IRL757 (middel mod apati ifm Parkinsons): https://irlab.se/mfn_news/irlab-enters-a-development-collaboration-for-irl757-as-a-novel-treatment-for-apathy/

      1 Reply Last reply
      0
      • K Offline
        K Offline
        Kjølstad
        wrote on sidst redigeret af
        #22

        IRLAB: Aftalen omfatter up front 3 mio. $ med option yderligere 5,5 mio. $ i milepælsbetalinger, samt fælles produktudvikling. Spændende at se deres regnskab, som kommer i dag.

        1 Reply Last reply
        0
        • K Offline
          K Offline
          Kjølstad
          wrote on sidst redigeret af
          #23

          IRLAB: Link til regnskabmeddelelse: https://view.news.eu.nasdaq.com/view?id=b382108fa4f0ea3918dfb1ad2b2086216&lang=en&src=listed

          1 Reply Last reply
          0
          • K Offline
            K Offline
            Kjølstad
            wrote on sidst redigeret af
            #24

            IRLAB: Det ser lovende ud .... 🙂

            1 Reply Last reply
            0
            • P Offline
              P Offline
              ProinvestorNEWS
              wrote on sidst redigeret af
              #25

              Bioportos omsætningsfremgang drevet af stærk vækst for NGAL-test i USA https://www.proinvestor.com/investornyt/1156584/bioportos-omsaetningsfremgang-drevet-af-staerk-vaekst-for-ngal-test-i-usa

              1 Reply Last reply
              0
              • exitnuE Offline
                exitnuE Offline
                exitnu
                wrote on sidst redigeret af
                #26

                XBRANE AND STADA PARTNER WITH VALORUM BIOLOGICS TO COMMERCIALIZE RANIBIZUMAB BIOSIMILAR CANDIDATE IN THE US

                Link Preview Image
                » Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the USXbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US – Xbrane

                favicon

                (xbrane.com)

                1 Reply Last reply
                0
                • K Offline
                  K Offline
                  Kjølstad
                  wrote on sidst redigeret af
                  #27

                  IRLAB: Dejlig dag. Regnskabet og perspektiverne belønnes ?

                  1 Reply Last reply
                  0
                  • K Offline
                    K Offline
                    Kjølstad
                    wrote on sidst redigeret af
                    #28

                    ADMA: Ligeledes i festlig stemning .... og jeg fejrer dagen med mojito på terrassen:-)

                    1 Reply Last reply
                    0
                    • F Offline
                      F Offline
                      Fandel
                      wrote on sidst redigeret af
                      #29

                      Godmorgen...

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #30

                        Photocure : Asieris' NDA For Cevira Accepted By NMPA For Regulatory Review In China https://www.proinvestor.com/investornyt/1158788/photocure-asieris-nda-for-cevira-accepted-by-nmpa-for-regulatory-review-in-china

                        1 Reply Last reply
                        0
                        • L Offline
                          L Offline
                          LP90
                          wrote on sidst redigeret af
                          #31

                          God nyhed med Photocure når man nu har lidt for mange af dem også 🙂

                          1 Reply Last reply
                          0
                          • F Offline
                            F Offline
                            Fandel
                            wrote on sidst redigeret af
                            #32

                            Godmorgen...

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              LP90
                              wrote on sidst redigeret af
                              #33

                              Godmorgen 🙂

                              1 Reply Last reply
                              0
                              • exitnuE Offline
                                exitnuE Offline
                                exitnu
                                wrote on sidst redigeret af
                                #34

                                Calliditas’ Partner Everest Medicines Starts Commercial Launch of Nefecon in China

                                Link Preview Image
                                Calliditas Therapeutics AB

                                Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

                                favicon

                                Calliditas Therapeutics AB (www.calliditas.se)

                                1 Reply Last reply
                                0
                                • exitnuE Offline
                                  exitnuE Offline
                                  exitnu
                                  wrote on sidst redigeret af
                                  #35

                                  “This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN,” said Renee Aguiar-Lucander, CEO.

                                  1 Reply Last reply
                                  0
                                  • F Offline
                                    F Offline
                                    Fandel
                                    wrote on sidst redigeret af
                                    #36

                                    Godmorgen...

                                    1 Reply Last reply
                                    0
                                    • L Offline
                                      L Offline
                                      LP90
                                      wrote on sidst redigeret af
                                      #37

                                      Morning 🙂

                                      1 Reply Last reply
                                      0
                                      • exitnuE Offline
                                        exitnuE Offline
                                        exitnu
                                        wrote on sidst redigeret af
                                        #38

                                        Genovis - Interim Report January – March 2024

                                        https://mb.cision.com/Main/1712/3976051/2798815.pdf

                                        "Best quarter for enzyme business in analytics and stronger cash position"

                                        1 Reply Last reply
                                        0
                                        • F Offline
                                          F Offline
                                          Fandel
                                          wrote on sidst redigeret af
                                          #39

                                          Godmorgen...

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper